Amanda Forys, MSPH: Do you think that a patient is considering—in oncology sometimes you hear the general sentiment that sometimes patients aren’t as worried about costs as they might be with a different condition because it’s oncology, and it just gets your attention and there’s so much attention to it. Patients will sometimes go to extremes to make sure that they’re able to cover the cost of their medication. I’m not saying they won’t in other diseases, but oncology is just kind of one of those special ones that really gets people’s attention and they’ll do what they can for their care.
What are patients looking for in terms of a cost savings, and is that alone—I know you talked a little bit about efficacy and feeling safe taking it—how much do you think cost plays in that decision to switch to a biosimilar or take one?
Christy M. Gamble, JD, DrPH, MPH: It really depends on the patient. You have some patients in oncology that are willing to take the risk, like you said: “Whatever it takes to fix or treat my condition or manage my condition.” But you have some patients who just simply can’t afford it. You have populations of color and low-income patients that are oncology patients but they can’t afford it.
That’s when the conversation comes down to what we call the 5 As of access: you have accessibility: is it easy for me to get this medication? Then you have availability: is it available to me immediately? You have accommodation: can I get to it at certain times, can I go to my local pharmacy—my 24-hour pharmacy—and access this drug? Affordability of course is key. When it comes to those that are insured, am I able to cover the co-pay? That’s where cost comes into play. And then acceptability: am I able to get this from my provider, [and] is my provider willing to offer this as an alternative?
So, there are so many different things that come into play; cost is just one of them. But it’s really the ease of getting to it. The least amount of barriers, the more likely you are to see a patient who’s willing to take a biosimilar versus those who are facing some significant barriers. Like I said, populations of color and low-income patients are more likely not to take biosimilars because of all of the barriers including cost that come into play with the therapy.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarized the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.